Compare · AZN vs ENTA
AZN vs ENTA
Side-by-side comparison of AstraZeneca PLC (AZN) and Enanta Pharmaceuticals Inc. (ENTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and ENTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $282.65B, about 1116.8x ENTA ($253.1M).
- AZN has been more active in the news (22 items in the past 4 weeks vs 10 for ENTA).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- Enanta Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $282.65B
- $253.1M
- 1M return
- +11.17%
- -
- 1Y return
- +103.51%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2013
- News (4w)
- 22
- 10
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC
Latest ENTA
- SEC Form 10-K filed by Enanta Pharmaceuticals Inc.
- SEC Form SCHEDULE 13G filed by Enanta Pharmaceuticals Inc.
- Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.
- Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
- SEC Form 8-K filed by Enanta Pharmaceuticals Inc.
- SEC Form 8-K filed by Enanta Pharmaceuticals Inc.
- Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
- Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)